Protocol Ledger

NCT03541668 · Phase III · COMPLETED

Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)

Interventional Phase III clinical trial protocol NCT03541668 sponsored by Tasly Biopharmaceuticals Co in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-05-18 Enrollment: 674 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03541668
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)674 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03541668
Protocol FieldVerified Registry Value
NCT IdentifierNCT03541668
Consolidated Lead SponsorTasly Biopharmaceuticals Co
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment674 participants (ACTUAL)
Registered Start Date2018-05-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03541668
Hospital Research SiteLocationSite Profile
Xuanwu Hospital Capital Medical UniversityBeijing, ChinaOpen Hospital Dossier ->
The First Hospital of Hebei Medical UniversityShijiazhuang, ChinaOpen Hospital Dossier ->
The Second Hospital of Hebei Medical UniversityShijiazhuang, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI